JP2018533560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533560A5 JP2018533560A5 JP2018517826A JP2018517826A JP2018533560A5 JP 2018533560 A5 JP2018533560 A5 JP 2018533560A5 JP 2018517826 A JP2018517826 A JP 2018517826A JP 2018517826 A JP2018517826 A JP 2018517826A JP 2018533560 A5 JP2018533560 A5 JP 2018533560A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- compound
- cancer
- administering
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 31
- 206010028980 Neoplasm Diseases 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 25
- 201000011510 cancer Diseases 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 22
- 229940079593 drug Drugs 0.000 claims 11
- -1 adamantane compound Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 6
- 230000003115 biocidal effect Effects 0.000 claims 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000003242 anti bacterial agent Substances 0.000 claims 5
- 229940088710 antibiotic agent Drugs 0.000 claims 5
- 229940034982 antineoplastic agent Drugs 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- GKNUOVITASQZAQ-AWEZNQCLSA-N ethyl 4-[(2s)-2-amino-3-phenylpropanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](N)CC1=CC=CC=C1 GKNUOVITASQZAQ-AWEZNQCLSA-N 0.000 claims 4
- 230000035755 proliferation Effects 0.000 claims 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 3
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 3
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims 3
- 229960002626 clarithromycin Drugs 0.000 claims 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 3
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 3
- 229960000885 rifabutin Drugs 0.000 claims 3
- CAOTVXGYTWCKQE-RZTFFZPQSA-N (7s)-3-(4-chlorophenyl)-n-(pyridin-4-ylmethyl)adamantane-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1(C2)CC(C3)(C(=O)NCC=4C=CN=CC=4)C[C@H]2CC3C1 CAOTVXGYTWCKQE-RZTFFZPQSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 238000001516 cell proliferation assay Methods 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 2
- OECLPECEPAYMGH-UHFFFAOYSA-N 3-(4-chlorophenyl)adamantane-1-carboxylic acid Chemical compound C1C(C(=O)O)(C2)CC(C3)CC1CC32C1=CC=C(Cl)C=C1 OECLPECEPAYMGH-UHFFFAOYSA-N 0.000 claims 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- FGYMBVGBIYRUHB-UQKRIMTDSA-N ethyl 4-[(2S)-2-amino-3-phenylpropanoyl]piperazine-1-carboxylate sulfuric acid Chemical compound S(=O)(=O)(O)O.C(C)OC(=O)N1CCN(CC1)C([C@@H](N)CC1=CC=CC=C1)=O FGYMBVGBIYRUHB-UQKRIMTDSA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical class OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 208000037843 metastatic solid tumor Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237925P | 2015-10-06 | 2015-10-06 | |
| US62/237,925 | 2015-10-06 | ||
| PCT/IB2016/001526 WO2017060771A2 (en) | 2015-10-06 | 2016-10-06 | Combination therapies for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533560A JP2018533560A (ja) | 2018-11-15 |
| JP2018533560A5 true JP2018533560A5 (enExample) | 2019-11-14 |
| JP6963545B2 JP6963545B2 (ja) | 2021-11-10 |
Family
ID=58446480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517826A Active JP6963545B2 (ja) | 2015-10-06 | 2016-10-06 | 癌を治療するための併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9844540B2 (enExample) |
| EP (1) | EP3359255A4 (enExample) |
| JP (1) | JP6963545B2 (enExample) |
| KR (1) | KR20180058716A (enExample) |
| CN (1) | CN108136207A (enExample) |
| AU (1) | AU2016336133B2 (enExample) |
| BR (1) | BR112018003232A2 (enExample) |
| CA (1) | CA2997671A1 (enExample) |
| HK (1) | HK1259342A1 (enExample) |
| MX (1) | MX382754B (enExample) |
| RU (1) | RU2727474C2 (enExample) |
| WO (1) | WO2017060771A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4134076A1 (en) | 2014-10-24 | 2023-02-15 | Redhill Biopharma Ltd. | Therapy for inhibition of single-stranded rna virus replication |
| WO2018195434A1 (en) | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| CA3060509A1 (en) | 2017-04-21 | 2018-10-25 | Federica Sotgia | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
| KR20200010343A (ko) | 2017-05-19 | 2020-01-30 | 루넬라 바이오테크 인코포레이티드 | 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제 |
| WO2018213764A1 (en) | 2017-05-19 | 2018-11-22 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| EP3644988B1 (en) | 2017-06-26 | 2023-02-22 | Lunella Biotech, Inc. | Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells |
| JP2020534285A (ja) | 2017-09-15 | 2020-11-26 | アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 投与および処置の方法 |
| EP3681494A4 (en) * | 2017-09-15 | 2021-08-04 | Ampersand Biopharmaceuticals, Inc. | INHIBITION OF SPONTANEOUS METASTASIS BY PROTEIN INHIBITORS OF CYSTEIN PROTEASES |
| BR112021013952A2 (pt) * | 2019-01-16 | 2021-11-16 | Apogee Biotechnology Corp | Métodos de indução de uma resposta imunológica anticâncer |
| WO2020154716A1 (en) * | 2019-01-26 | 2020-07-30 | University Of Rochester | Compositions and methods for treating prostate cancer |
| CA3174438A1 (en) * | 2020-03-10 | 2021-09-16 | Redhill Biopharma Ltd. | Treatment of coronavirus infection |
| US11471448B2 (en) | 2020-12-15 | 2022-10-18 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia |
| CN119700770A (zh) * | 2025-01-09 | 2025-03-28 | 首都医科大学附属北京佑安医院 | 氯法齐明在制备修复肠黏膜或改善肠道菌群药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2189001A1 (en) * | 1994-04-26 | 1995-11-02 | Nobuhiro Narita | Medicinal composition as a remedy for nonsmall cell lung cancer |
| AUPP437698A0 (en) * | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
| DE59909210D1 (de) * | 1998-07-20 | 2004-05-19 | Wilex Ag | Urokinase-Inhibitoren |
| AUPR644301A0 (en) * | 2001-07-17 | 2001-08-09 | Unisearch Limited | Method and composition for treatment of cancer |
| US6864264B1 (en) * | 2002-08-20 | 2005-03-08 | Gloria L. Anderson | 1-adamantyl chalcones for the treatment of proliferative disorders |
| DE10323898A1 (de) * | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
| DE102004057195A1 (de) * | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
| US20060142304A1 (en) * | 2004-12-27 | 2006-06-29 | Michael Southall | Method for treating or preventing pruritic and neurogenic skin disorders |
| US20060270631A1 (en) * | 2005-05-26 | 2006-11-30 | Smith Charles D | Methods for the treatment and prevention of angiogenic diseases |
| ES2528451T3 (es) * | 2005-06-17 | 2015-02-10 | Apogee Biothechnology Corporation | Inhibidores de esfingosina cinasa |
| TWI405756B (zh) * | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
| US20080226624A1 (en) * | 2007-03-07 | 2008-09-18 | Wolfgang Schmalix | Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect |
| HRP20190045T1 (hr) * | 2008-02-08 | 2019-03-08 | Red Hill Biopharma Ltd. | Metode i sastavi za liječenje upalne bolesti crijeva |
| TWI573590B (zh) * | 2011-09-20 | 2017-03-11 | 雷希爾生藥有限公司 | 治療自體免疫疾病之組成物及方法 |
| EP3560497A1 (en) * | 2012-08-30 | 2019-10-30 | The Texas A&M University System | Compositions and methods for drug-sensitization or inhibition of a cancer cell |
| EP4134076A1 (en) * | 2014-10-24 | 2023-02-15 | Redhill Biopharma Ltd. | Therapy for inhibition of single-stranded rna virus replication |
-
2016
- 2016-10-06 KR KR1020187007757A patent/KR20180058716A/ko not_active Ceased
- 2016-10-06 AU AU2016336133A patent/AU2016336133B2/en not_active Ceased
- 2016-10-06 BR BR112018003232A patent/BR112018003232A2/pt not_active IP Right Cessation
- 2016-10-06 RU RU2018109902A patent/RU2727474C2/ru active
- 2016-10-06 MX MX2018004309A patent/MX382754B/es unknown
- 2016-10-06 EP EP16853154.9A patent/EP3359255A4/en active Pending
- 2016-10-06 CN CN201680058309.3A patent/CN108136207A/zh active Pending
- 2016-10-06 CA CA2997671A patent/CA2997671A1/en not_active Abandoned
- 2016-10-06 HK HK19101708.0A patent/HK1259342A1/zh unknown
- 2016-10-06 US US15/287,381 patent/US9844540B2/en active Active
- 2016-10-06 WO PCT/IB2016/001526 patent/WO2017060771A2/en not_active Ceased
- 2016-10-06 JP JP2018517826A patent/JP6963545B2/ja active Active
-
2017
- 2017-11-07 US US15/805,682 patent/US10463654B2/en active Active
-
2019
- 2019-09-17 US US16/573,325 patent/US10946000B2/en active Active
-
2021
- 2021-01-12 US US17/147,093 patent/US11633385B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533560A5 (enExample) | ||
| RU2018109902A (ru) | Виды комбинированной терапии для лечения рака | |
| DK2099442T3 (en) | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy | |
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| JP2021098728A5 (enExample) | ||
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| JP2015519329A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| JP2014528901A5 (enExample) | ||
| KR20170033358A (ko) | 브루톤 티로신 키나아제 저해제의 신규한 제제 | |
| JP2015523397A5 (enExample) | ||
| JP2015536964A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| JP2009500443A5 (enExample) | ||
| JP2015522630A5 (enExample) | ||
| RU2015126661A (ru) | Пероральная комбинация для предотвращения и лечения патологий мочевого пузыря, органов малого таза и мочеполового аппарата | |
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| JP2018522028A5 (enExample) | ||
| RU2013137645A (ru) | Аналоги цистамина, применяемые для лечения болезни паркинсона | |
| JP2015508765A5 (enExample) | ||
| CN104918630A (zh) | 抗药性癌细胞的抑制 | |
| JP2015507020A5 (enExample) | ||
| JP2013528215A5 (enExample) | ||
| WO2012117396A1 (en) | Tyrphostin derivative in combination with cytotoxic compounds for treating cancer |